Inventiva S.A.
NASDAQ:IVABiotechnology
+$0.02 today
- Market cap
- $176.22M
- Beta
- 0.88
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.56
Volume 3.54M
Average 0.45M
IVA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Inventiva S.A.NASDAQ: IVA
Cash & Equivalents · Q4 FY2025 · quarter ended Dec 2025
Cash & equivalents rises 2.8% from a year ago
Cash & equivalents stood at €99.27M at the end of Q4 FY2025, up 2.8% from a year earlier. Over 3 fiscal years it compounded at +4.6% a year.
Context
- Cash & equivalents amounted to 39.9% of total assets at the end of Q4 FY2025, down 41.3 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +2.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
EUR · from the balance sheet
- Latest · FY2025
- 99.27M EUR
- Year-over-year change
- +2.8%
- 4-year CAGR
- +3.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 99.27M | +2.8% |
| FY2024 | 2024-12-31 | 96.56M | +258.7% |
| FY2023 | 2023-12-31 | 26.92M | -69.0% |
| FY2022 | 2022-12-31 | 86.74M | +0.2% |
| FY2021 | 2021-12-31 | 86.55M | — |
Cash & Equivalents vs competitors
How IVA compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +2.8% is the 5th highest of 10, against a peer median of -34.2%.
- Cash & equivalents amounts to 39.9% of total assets for IVA, versus a peer median of 28.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $184.15M USD | +283.0% | +35.0% | 76.2% | |
| Mar 2026 | $118.64M USD | -34.2% | +5.5% | 41.1% | |
| Dec 2025 | €99.27M EUR | +2.8% | +4.6% | 39.9% | |
| Mar 2026 | $80.89M USD | +50.4% | +1.8% | 59.9% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $58.69M USD | +113.8% | +48.2% | 40.2% |
| Mar 2026 | $34.93M USD | -42.0% | -9.8% | 11.1% | |
| Mar 2026 | $28.37M USD | +54.6% | +20.6% | 28.2% | |
| Mar 2026 | $24.99M USD | -80.0% | +6.4% | 25.0% | |
| Mar 2026 | $14.63M USD | -56.0% | -52.4% | 8.2% | |
| Mar 2026 | $12.06M USD | -59.0% | -40.4% | 8.1% | |
| Peer median (excluding IVA) | — | -34.2% | +5.5% | 28.2% | |
Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 86.55M | 86.74M | 26.92M | 96.56M | 99.27M |
| Short-term Investments | 0 | 1.05M | 70K | 0 | 0 |
| Net Receivables | 11.59M | 279K | 15.71M | 12.16M | 9.12M |
| Inventory | 392K | 373K | 417K | 0 | 0 |
| Other Current Assets | 9.59M | 9.35M | 69K | 349K | 131.5M |
| Total Current Assets | 115.58M | 106.38M | 48.19M | 111.51M | 243.84M |
| Property, Plant & Equipment (Net) | 3.2M | 7.39M | 9.13M | 5.01M | 2.98M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 770K | 568K | 541K | 48K | 181.92K |
| Long-term Investments | 1.75M | 700K | 1.43M | 1.14M | 526.78K |
| Tax Assets | 699K | 0 | 225K | 217K | 190.92K |
| Other Non-current Assets | (2K) | 968K | 10.05M | 1.05M | 1.16M |
| Total Non-current Assets | 6.41M | 9.62M | 21.37M | 7.46M | 5.04M |
| Total Assets | 121.99M | 116M | 69.56M | 118.97M | 248.88M |
| Account Payables | 14.6M | 19.36M | 37.68M | 32.86M | 26.01M |
| Short-term Debt | 1.24M | 4.57M | 3.01M | 3.35M | 30.27M |
| Tax Payables | 1.06M | 2.14M | 3.57M | 3.92M | 0 |
| Deferred Revenue | 0 | 6K | 6K | 0 | 0 |
| Other Current Liabilities | 5.74M | 2.28M | 5.63M | 73.4M | 8.29M |
| Total Current Liabilities | 22.85M | 30.7M | 50.16M | 120.73M | 77.35M |
| Long-term Debt | 8.75M | 25.43M | 27.91M | 46.33M | 24.77M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 55K | 0 | 107K | 125.95K |
| Other Non-current Liabilities | 1.43M | 11.11M | 19.25M | 56.31M | 172.9M |
| Total Non-current Liabilities | 10.27M | 39.83M | 51.43M | 104.88M | 200.57M |
| Total Liabilities | 33.12M | 70.53M | 101.59M | 225.61M | 277.91M |
| Common Stock | 409K | 421K | 521K | 957K | 1.93M |
| Retained Earnings | (49.64M) | (54.27M) | (110.43M) | (184.21M) | (354.14M) |
| Accumulated OCI | (26.98M) | (74.56M) | (123.99M) | (172.55M) | (204.55M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 88.87M | 45.48M | (32.03M) | (106.65M) | (29.04M) |
| Total Debt | 10.12M | 34.51M | 37.49M | 54.33M | 59.4M |
| Net Debt | (76.43M) | (52.22M) | 10.57M | (42.23M) | (39.87M) |
Inventiva S.A.
NASDAQ:IVA
Intrinsic Alpha fair value
Locked
Current Price
$3.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.